EUVIMEDEUVIMED entdecken
Editorial

The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?

Michael J Fossler, C Edwin Garner

Clinical Pharmacology in Drug Development · 2026-03 · 15 (3)

DOI: 10.1002/cpdd.70046 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.03.2026. Verfasst von Michael J Fossler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology in Drug Development, Ashburn, VA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Clinical Pharmacology in Drug Development, Ashburn, VA, USA.
  • Strategic Consulting, Cytel, Waltham, MA, USA.
  • Mammoth Pre-Clinical Consulting, Placitas, NM, USA.
  • Modeling and Simulation, Resero Analytics, Indianapolis, IN, USA.

Zitieren

APA

Fossler, M. J., & Garner, C. E. (2026). The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?. Clinical Pharmacology in Drug Development, 15(3). https://doi.org/10.1002/cpdd.70046

Vancouver

Fossler MJ, Garner CE. The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?. Clinical Pharmacology in Drug Development. 2026;15(3). doi:10.1002/cpdd.70046

BibTeX
@article{Fossler2026,
  author = {Fossler, Michael J and Garner, C Edwin},
  title = {The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cpdd.70046}
}
Kostenlos starten →